{"schema_version":"secwatch.filing_event.v1","accession":"0000031791-26-000016","form_type":"8-K","ticker":"RVTY","cik":"0000031791","company_name":"REVVITY, INC.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.556051+00:00","generated_at":"2026-05-14T23:36:37.675711+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revvity Q1 adj EPS $1.06 beats $1.01 YoY; revenue $711M +7%; plans China IDX divestiture","bullets":["Q1 GAAP EPS $0.37 vs $0.35 YoY; adjusted EPS $1.06 vs $1.01; revenue $711M (+7% YoY).","Pro forma (ex-China IDX) revenue $687M, adj EPS $1.04 vs $0.95 YoY.","Signed LOI to sell China Immunodiagnostics business for up to $200M; expects close by 2027.","China IDX represented ~6% of FY2025 total revenue; definitive agreement expected Q2 2026.","Full-year 2026 guidance updated on pro forma basis; management to discuss on call."],"urls":{"canonical":"https://secwatch.observer/filing/0000031791-26-000016","json":"https://secwatch.observer/filing/0000031791-26-000016.json","markdown":"https://secwatch.observer/filing/0000031791-26-000016.md","text":"https://secwatch.observer/filing/0000031791-26-000016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/0000031791-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/pki-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:36:37.675711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5fde824233493d0054c3f3288f83cea28a766dc","claim":"REVVITY, INC. reported first quarter ended April 5, 2026 results: revenue $711 million, EPS $0.37.","evidence_excerpt":"OR IMMEDIATE RELEASE May 5, 2026 Revvity Announces Financial Results for the First Quarter of 2026 • Revenue of $711 million; pro forma revenue of $687 million; 7% revenue growth; 3% organic gro wth; 6% pro forma organic growth • GAAP EPS from continuing operations of $0.37 ; adjusted EPS from continuing operations of $1.06 ; GAAP pro forma EPS from continuing operations of $0.40; pro forma adjusted EPS from continuing operations of $1.04 • Announces intention to divest China Immunodiagnostics business • Updates full year 2026 guidance WALTHAM, Mass.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000016/0000031791-26-000016-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended April 5, 2026"},{"label":"Revenue","value":"$711 million"},{"label":"EPS","value":"$0.37"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}